CA
NZ
UK
AU
IND
US
NanoViricides has established a flexible financing mechanism through an at-market stock sales agreement, enabling the company to issue shares as needed. The arrangement, finalized with D. Boral Capital LLC, allows the antiviral drug developer to access capital markets without the constraints of a fixed …
The settlement, disclosed in a regulatory filing, closes a probe by the U.S. Department of Justice and the Office of Inspector General without the company admitting wrongdoing. EyePoint will also enter a Corporate Integrity Agreement with the Department of Health and Human Services, mandating …
Hims & Hers Health has announced the resignation of its Chief Accounting Officer, the latest in a series of leadership changes at the telehealth provider. The departure follows a series of similar disclosures and comes as the company navigates a period of steady but …
IBio has announced that its upcoming annual shareholder gathering will take place in mid‑October, prompting a revision of the deadlines for shareholder proposals as the company’s shares continue to face downward pressure. The meeting will be held on a date set for the middle …
An executive at Inspire Medical Systems sold shares last week, a move that has drawn attention to the accelerating demand for obstructive sleep apnea treatments. The transaction, disclosed in a regulatory filing, coincides with a broader uptick in investor interest in sleep apnea stocks, …
Intuitive Surgical’s stock retreated this week as investors weighed solid second‑quarter results against a tempered outlook for procedure growth. The robotic‑surgery leader reported a 16% year‑over‑year increase in worldwide procedures, driven by a 15% rise in da Vinci surgeries and a 36% surge in …
Devyser Diagnostics posted an 80% gross margin for the second quarter of 2026, keeping the figure in line with its internal target even as sales to its largest distributor fell short of expectations. The shortfall rippled through the European healthcare diagnostics arena, where investors …
EnGene Therapeutics is positioning its experimental bladder cancer therapy detalimogene as a potential best-in-class treatment after reporting a 54% complete response rate in its mid-stage LEGEND study. The company, which filed its latest corporate update on July 17, 2026, is targeting a biologics license …
Aditxt (NASDAQ: ADTX) restructured its senior secured financing on July 16, 2026, by cancelling an existing note and issuing two replacement notes of the same combined principal amount. The amendment also admits a new investor, broadening the pool of capital backers while leaving the …
Avantor (NYSE: AVTR) has successfully refinanced €374,208,296.62 of Euro‑denominated term loans, achieving a 50‑basis‑point reduction in its cost of borrowing and extending its debt maturity profile to October 2032. The newly issued Incremental B‑7 Euro Term Loans are priced at EURIBOR plus a spread …
Please wait processing your request...